A phase III parallel-group comparison study of HOB-294 in patients with overactive bladder.
Phase of Trial: Phase III
Latest Information Update: 20 May 2016
At a glance
- Drugs Oxybutynin (Primary)
- Indications Overactive bladder
- Focus Therapeutic Use
- Sponsors Hisamitsu Pharmaceutical
- 11 Aug 2011 Status changed from planning to completed, according to results published in a Hisamitsu media release.
- 14 Nov 2009 New trial record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History